Erasca at an Inflection - Hold Through ERAS-0015 Readouts, Trim on Weakness
Erasca (ERAS) sits squarely between high upside from ERAS-0015 clinical progress and material headline risk from a patent infringement claim and a securities investigation. We recommend Hold: existing holders should keep positions sized but use a hard stop; new entrants should wait for clearer data or a resolution of the legal noise. Trade plan pro…